RSV infection study in older adults
Part of Infections clinical trials.
This study tests how older adults' immune systems respond to a mild RSV virus given as a nasal spray. It helps researchers understand RSV and may lead to better vaccines or treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 65 and 75 years old.
- You must be generally healthy, with no significant heart, lung, or immune conditions.
- You cannot have asthma, COPD, or other chronic lung disease.
- You cannot have diabetes or a weakened immune system.
- You must not smoke, vape, or use nicotine products regularly.
- You must be willing to stay in quarantine and have a nasal spray with a mild RSV virus.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental vaccine to see if it is safe for healthy adults. The vaccine is made with mRNA technology and aims to protect against RSV, a common respiratory virus.
This study looks at how common RSV (a virus that can cause coughing and breathing problems) is in adults with a recent respiratory infection. If you have a cough or other cold-like symptoms and are 18 or older, you might be able to help by giving a sputum and saliva sample.
This study tests whether getting an RSV vaccine (a shot that protects against a common respiratory virus) can reduce the number of COPD flare-ups in people who have frequent episodes. If you qualify, you may receive the vaccine and be followed for a year to see if it helps keep you out of the hospital.
This study tests an RSV vaccine in adults aged 18 and older, especially those with chronic health issues like heart or lung disease. It aims to see how safe and effective the vaccine is at preventing RSV infections.
This study tests an RSV vaccine to see if it is safe and helps your immune system fight the virus. It's for older adults who are generally healthy, and it may help protect you from severe RSV illness.
This trial tests a new RSV vaccine for people aged 60 and above. RSV is a common virus that can cause serious breathing problems in older adults. The study will see if the vaccine is safe and helps protect you from RSV.
Hear when a new RSV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.